Holika Dahan 2026 Wishes from Norden Life Sciences

#holikadahan #nordenlifesciences #holi2026 #holi #happyholi #holifestival #holika #festivalofcolors #pcdpharmafranchise #pharmaindia #medicalindustry #pharmagrowth #pharmacompanyindia #healthcareindustry #pharmaceuticalindustry

Novartis、2025〜2030年の売上CAGRを5〜6％に上方修正 Kisqali・Scemblix含む30超の高価値候補薬が成長を牽引 | STELLANEWS.LIFE Novartisは2025〜2030年の売上成長見通しをCAGR＋5〜6％へ引き上げ、KisqaliやScemblixのピーク売上予測を上方修正。30以上の高価値候補薬と15件以上の主要試験結果が中期成長を支える計画を発表。

Novartis Raises 2025–2030 Sales Growth Outlook to +5–6% CAGR

🔗 Full article: stellanews.life/technology_c...

#Novartis #Biopharma #Kisqali #Scemblix #PharmaGrowth #R&D #Pipeline #CAGR #InvestorRelations #LifeSciences

CMO/CDMO market Poised for Growth, Expected to Hit $48.05 Billion by 2034 with a 5.90% CAGR Market CAGR for CMO/CDMO is being driven by the rising new age contract producers striving for greater flexibility and responsiveness

📈 The CMO/CDMO Market is set to reach $48.05B by 2034 with a strong 5.90% CAGR! Explore growth drivers shaping the future of contract development & manufacturing. 🔬🚀 Read more: www.einpresswire.com/article/7870... #CMO #CDMO #Biotech #PharmaGrowth

Dry Eye Syndrome Market Forecasted to Reach USD 7.5 Billion By 2032, at an Impressive 4.56% CAGR | Global Healthcare Today Global Healthcare Today is an online news publication focusing on health & wellness: The latest news on healthcare and wellness

💧 The Dry Eye Syndrome Market is forecasted to hit USD 7.5 Billion by 2032 at 4.56% CAGR. Growing awareness and treatment innovation fuel expansion. 👁 #DryEyeSyndrome #HealthcareMarket #Ophthalmology #PharmaGrowth
Read More: www.globalhealthcaretoday.com/article/7764...

Peptide API Market Size, Growth Analysis, Report 2032 Peptide API Market 2025, Industry to reach USD 56.0 Billion, at a 4.92% CAGR by growing size, share, top company analysis, segments research, trends and forecast report 2024 to 2032

💊 Peptide power in modern medicine! APIs driving growth in oncology, diabetes, & rare disease therapies.
#PeptideDrugs #Biopharma #PharmaGrowth

www.marketresearchfuture.com/reports/pept...

The Catharanthine Market is set for steady growth, increasing from USD 879.91M in 2024 to USD 1,270.26M by 2032 at a CAGR of 4.37%.

Click for the full report link: www.credenceresearch.com/report/catha...

#CatharanthineMarket #PharmaGrowth #BiotechResearch #HealthcareTrends #GlobalMarket

💊 Smart Marketplace Solutions for Med & Pharma 🚀
Trust. Compliance. Visibility.
That’s what makes your pharma business succeed online.
At Microlevel Solutions, we help brands grow with:
✅ Optimized Listings
✅ Compliance-First Strategy
✅ Sales Growth
👉 microlevelsolution.com
#PharmaGrowth

Decongestant Market Trends, Growth, Forecast 2035 | MRFR - News and Updates Decongestant Market is estimated to register a CAGR of 6.48% during the forecast period and is estimated to reach USD 57.81 Billion by 2035. - News and Updates

Decongestant Market
🤧 Breathing easy! #Decongestant market surging as respiratory care demand rises 🌬️💊 #ColdFlu #PharmaGrowth

www.marketresearchfuture.com/press-releas...

Der Markt für In-silico-Arzneimittelforschung wird voraussichtlich bis 2034 ein Volumen von 13,76 Milliarden US-Dollar erreichen, bei einer bemerkenswerten jährlichen Wachstumsrate von 11,25 % - ekz-c... Marktübersicht für computergestützte Arzneimittelforschung (In Silico Drug Discovery):Marktforschungsbericht zum Markt für In Silico Drug Discovery nach Dienstleistungsart (Molekulare Modellierung, Co...

Herceptin-Biosimilars
💊🎯 Markt klettert auf $13.76 Mrd. bis 2034 📈 +11.25% CAGR 🌟
#Biosimilars #Oncology #PharmaGrowth

ekz-crosstour.ch/2025/07/17/d...

Veterinary Autoimmune Disease Therapeutics Market Set to Grow at an Impressive CAGR of 10.02 Percent Through 2034 | USD 5.99 Billion Veterinary Autoimmune Disease Therapeutics Market is poised for significant expansion projected to reach USD 5 99 billion by 2034 growing at a CAGR of 10 02 percent during the forecast period This rob...

Veterinary Autoimmune Disease Therapeutics 🐶💉
Veterinary autoimmune disease market to grow 📊 — advancing pet health & treatment access 🐾
#VetCare #AnimalHealth #PetWellness #PharmaGrowth

www.openpr.com/news/4104817...

Anxiety Disorders and Depression Treatment Market Set to Grow at an Impressive CAGR of 3.72% Through 2034 | USD 19.45 Billion Anxiety Disorders and Depression Treatment Market Set to Grow at an Impressive CAGR of 3 72 Through 2034 USD 19 45 Billion The global Anxiety Disorders and Depression Treatment Market is poised for st...

Anxiety & Depression Treatment 🧠💙
Global #Anxiety & #Depression treatment market to soar 📊 as mental health awareness rises 🌍💡
#MentalHealthMatters #HealthcareMarket #Wellbeing #PharmaGrowth

www.openpr.com/news/4102707...

Pharma Regulatory Management System Market Projected to Hit USD 10.0 Billion by 2032, at a Exceptional CAGR 8.41% - Industry Today Estimated at USD 5.24 billion in 2024, the market is projected to reach USD 10.0 billion by 2032, growing at a robust CAGR of 8.41% from 2025 to 2032.

Pharma Regulatory Management Systems – Compliance goes digital! 📑💡 $100B by 2032, 8.41% CAGR
#HealthRegulations #PharmaGrowth #DigitalHealth

industrytoday.co.uk/health_and_s...

Cough Remedies Market Poised to Growth USD 19.2 Billion by 2032 with Thriving CAGR of 3.62% - Industry Today with global market size projected to rise from USD 14.45 billion in 2024 to USD 19.2 billion by 2032, growing at a CAGR of 3.62% over the forecast period

Cough Remedies Market – Cold & flu season boost! 🤧💊 $4,765.8B by 2032, 7.90% CAGR.
#ColdRelief #HealthCareTrends #PharmaGrowth

industrytoday.co.uk/health_and_s...

Botanical and Plant-Derived Drugs Market Expected to Hit USD 55.5 Billion by 2032 with a Remarkable 4.79% CAGR - Industry Today With a market size of USD 38.16 billion in 2024, up from USD 36.42 billion in 2023, the sector is forecasted to reach USD 55.5 billion by 2032, growing at a CAGR of 4.79% during the 2025–2032 period

Botanical & Plant-Derived Drugs Market – Green pharma surge! 🌱💊 $55.5B by 2032, 4.79% CAGR.
#HerbalMedicine #NaturalTherapies #PharmaGrowth

industrytoday.co.uk/health_and_s...

Throat Sprays Market Forecasted to Reach USD 3.4 Billion By 2032, at an Impressive 3.78% CAGR - Industry Today Throat Sprays Market CAGR is expected to be around 3.78% during the forecast period 2024 - 2032

😷 Throat Spray Market is clearing up—projected to hit $3.4B by 2032 with 3.78% CAGR
#ENTCare #ColdFluSeason #PharmaGrowth

industrytoday.co.uk/health_and_s...

Gedeon Richter reports 8% pharma growth in first half 2025 Investing.com -- Hungarian pharmaceutical company Gedeon Richter on Wednesday reported 8% constant exchange rate growth in pharmaceutical revenue for the first half of 2025, driven primarily by its Vraylar antipsychotic medication and women’s healthcare portfolio. The company posted pharmaceutical revenue of HUF 457.6 billion (€1.13 billion) for the period, which fell 2% below consensus estimates of HUF 466.9 billion. Clean EBIT reached HUF 148.2 billion, representing 15% growth at constant exchange rates, with a margin of 31.8%. Gedeon Richter’s central nervous system (CNS) segment saw Vraylar revenues increase 14.4% year-over-year, while Reagila royalties grew 3.6% (0.1% at constant exchange rates), with slower performance attributed to timing of shipments. The segment’s clean EBIT rose 22.5%, achieving an 86% margin in the first half and 90.5% in the second quarter, supported by modest R&D increases and a HUF 4.5 billion milestone payment. The women’s healthcare segment delivered 12.9% revenue growth (10.2% at constant exchange rates), led by strong performances from Ryeqo (+96.3%) and Drovelis (+65.6%). Despite this top-line growth, the segment’s clean EBIT declined 17.7%, with margin contracting to 16.4% due to elevated cost pressures, particularly from R&D investments including a new R&D hub in Belgium. The biosimilars segment grew 11% (8.9% at constant exchange rates), driven by CDMO sales and Teriparatide. Clean EBIT improved to HUF -8.5 billion from HUF -11.0 billion a year earlier, mainly due to a 28% reduction in R&D spending. Generic medicines revenue increased 7.7% (5.2% at constant exchange rates), with growth led by Poland (+12.5%) and Russia (+23.4%). Clean EBIT in this segment grew 5.2% while margin slightly decreased to 16.7%. The company noted that foreign exchange impacts and increased taxes caused a 13% year-over-year decrease in earnings per share. Gedeon Richter reiterated its full-year 2025 guidance, expecting pharmaceutical revenue growth of approximately 10% at constant exchange rates (€2.3-2.4 billion) and clean EBIT growth of around 10%. Management indicated that 2025 performance will be more weighted toward the second half of the year and noted that milestone income will be significantly lower in 2025 compared to 2024. The company’s share price stood at HUF 10,460, with Jefferies analysts maintaining a buy rating and a price target of HUF 13,390, representing 28% upside potential. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if GDRB is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #GedeonRichter #PharmaGrowth #Healthcare #Investing #Pharmaceuticals

Platinum Based Cancer Drug Market Forecasted to Reach USD 3.0 Billion By 2032, at an Impressive 4.47% CAGR - Industry Today As of 2024, the market is valued at USD 2.12 billion and is projected to reach USD 3.0 billion by 2032, growing at a CAGR of 4.47% during the forecast period

🏥🔬 #PlatinumCancerDrugs heading to $30 B by 2032, with 4.47% CAGR. Chemotherapy classics continuing strong. #Oncology #CancerTherapy #PharmaGrowth

industrytoday.co.uk/health_and_s...

Glaucoma Therapeutic Market Poised to Growth USD 6.89 Billion by 2032 with Thriving CAGR of 3.42% - Industry Today Glaucoma Therapeutics Market projected compound annual growth rate (CAGR) of 3.42% from 2025 to 2032, the market is anticipated to grow to USD 6.89 billion by 2032.

👁️‍🗨️#GlaucomaCare projected to be $6.89 B by 2032, rising at 3.42% CAGR. Vision-saving therapies scaling globally! #Ophthalmology #EyeHealth #PharmaGrowth

industrytoday.co.uk/health_and_s...

Best Press Release Distribution Services | iCrowdNewswire Looking for best press release distribution services? We offer Earned Media, Social Media & Now Paid Media Release to help you reach your target audience.

🌍 Global Alert!
🧠 Schizophrenia market set to soar to $13.41 BILLION by 2032!
📈 CAGR: 5.49% – Mental health innovation on the rise.
🔗 Read More
#MentalHealthMatters #HealthcareTrends #SchizophreniaTreatment #PharmaGrowth

icrowdnewswire.com

#BiomarkersMarket is set to reach USD 93.8 billion by 2029, driven by advancements in drug discovery, companion diagnostics, and key technologies like NGS & PCR.

lnkd.in/d-CaEqEG

#HealthcareInnovation #PharmaGrowth #Diagnostics #PrecisionMedicine #Biotech